GlassScriptPhysician profile
Erica Han
NPI 1073806022
$8,059.92
in general payments reported to CMS, 2019-2025
30 companies · $1,303 in 2025
The $1,303 reported for 2025 was more than what 85% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,008 · 2022: $1,550 · 2023: $3,502 · 2024: $696 · 2025: $1,303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318 · Consulting Fee: $2,050 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,318.01 |
| Consulting Fee | $2,050.00 |
| Education | $132.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,419.57 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $724.77 | 2021-2025 | Dupixent |
| Genzyme Corporation | $659.64 | 2021-2025 | |
| Glaxosmithkline, LLC. | $528.20 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $408.07 | 2021-2025 | Cuvitru, Takhzyro |
| Intersect Ent, INC. | $298.15 | 2021 | |
| Grifols USA, LLC | $256.01 | 2021-2024 | Xembify |
| Kaleo, INC. | $238.00 | 2021-2023 | Auvi-Q |
| Inspire Medical Systems, INC. | $194.68 | 2022-2023 | Inspire |
| Csl Behring | $183.67 | 2021-2025 | Hizentra |
| Optinose US, INC. | $174.29 | 2021-2025 | |
| Amgen INC. | $161.77 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $142.48 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $113.93 | 2021-2025 | |
| Alk-Abello, INC | $104.53 | 2021-2023 | Odactra, Grastek, Ragwitek |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $98.99 | 2023 | |
| Genentech USA, INC. | $49.39 | 2022-2023 | Xolair |
| Octapharma USA, INC. | $44.10 | 2021 | |
| Blueprint Medicines Corporation | $38.62 | 2024-2025 | Ayvakit |
| Pfizer INC. | $27.73 | 2022 | |
| Galderma Laboratories, L.P. | $26.45 | 2025 | Nemluvio |
| Kedrion Biopharma, INC. | $24.26 | 2022 | |
| Incyte Corporation | $23.85 | 2023 | Opzelura |
| Leo Pharma INC. | $22.33 | 2022 | |
| Phathom Pharmaceuticals, INC. | $19.74 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $19.50 | 2023 | |
| Paratek Pharmaceuticals, INC. | $18.56 | 2025 | Xhance |
| Hikma Pharmaceuticals USA | $17.19 | 2023 | Ryaltris |
| Eyevance Pharmaceuticals LLC | $11.29 | 2021 | |
| Organon LLC | $10.16 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erica Han listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.